Filed with ASX · · 2 pages · English
Cynata Therapeutics Limited provides an update on its proposed placement and corporate activities, including plans for a general meeting to seek shareholder approval for the placement expected to raise funds before costs. The company has confirmed that all material costs related to recent clinical trials have been settled and is maintaining its intellectual property portfolio.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
ASX ANNOUNCEMENT 13 November 2026 Update on Proposed Placement and Corporate Activities Key Points • General Meeting of shareholders to be held in January 2027 to seek approval of proposed Placement, which is now expected to raise ~$750k before costs • Placement terms are the same as the...
Cynata Therapeutics Limited on 6ix
